A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment

Trial Profile

A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Liver failure
  • Focus Pharmacokinetics
  • Sponsors Array BioPharma; Novartis
  • Most Recent Events

    • 09 Mar 2017 Status changed from recruiting to discontinued.
    • 30 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 31 Mar 2017.
    • 30 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top